1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Medicamen Biotech Limited

Medicamen Biotech Limited

253.75
INR
-13.15
(-4.93%)
6.93EPS
35.25P/E
3.39BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
86.26
86.14
67.84
79.1
99.57
104.81
103.3
92.26
94.5
111.35
141.64
127.84
145.82
139.88
Basic EPS, GAAP
0.11
0.49
0.48
4.95
9.03
10.28
10.94
9.93
12.19
11.73
8.63
5.59
7.11
7.09
Free Cash Flow per Basic Share
4.9
-3.73
5.06
1.22
-12.18
-9.73
-20.42
-4.25
-3.68
-10.19
-10.29
-8.14
-27.98
- -
Dividend per Share
- -
- -
- -
- -
0.99
- -
1.01
0.5
1
1
1
1
1
- -
Book Value per Share
18.55
18.07
17.92
25.46
63.77
74.05
99.22
108.78
119.89
152.79
161.31
166.62
203.17
- -
Tangible Book Value per Share
18.47
18.03
17.89
25.44
63.5
73.76
99
108.61
119.6
152.08
160.6
166.04
202.74
- -
Basic Weighted Avg Shares
8
9
10
10
11
12
12
12
12
13
13
13
14
14
Sales/Revenue/Turnover
732
778
673
825
1,115
1,226
1,255
1,127
1,154
1,409
1,793
1,625
1,978
2,026
Operating Margin (%)
4.94
3.82
5.4
11.72
13.22
12.6
13.76
15.22
16.46
13.41
9.71
4.18
6.25
5.97
Depreciation Expense
16
21
19
19
21
22
25
25
58
64
71
69
72
72
Net Income, GAAP
1
4
5
52
101
120
133
121
149
148
109
71
96
103
Effective Tax Rate (%)
47.3
- -
32.45
18.85
27.25
31.37
26.08
26.01
17.67
13.59
27.39
33.65
18.26
19.18
Profit Margin (%)
0.13
0.57
0.71
6.26
9.07
9.81
10.59
10.76
12.9
10.54
6.1
4.37
4.88
5.07
Working Capital
-37
38
34
107
498
476
476
428
503
808
750
864
1,358
- -
LT Debt
2
46
35
25
1
- -
24
64
51
9
13
37
62
- -
Total Equity
165
172
179
268
746
866
1,212
1,329
1,465
1,934
2,070
2,131
2,756
- -
Return on Invested Capital (%)
0.29
- -
1.28
12.42
15.93
11.31
10.92
8.78
8.95
7.63
5.11
1.83
3.51
- -
Return on Capital (%)
5.02
- -
6.85
18.64
17.78
13.51
11.87
9.08
9.91
8.93
6.81
4.02
4.33
- -
Return on Common Equity (%)
0.58
2.61
2.74
23.09
19.95
14.92
12.79
9.55
10.67
8.74
5.49
3.41
3.96
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
416
- -
LT Borrowings
- -
62
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
14
14
14
Market Capitalization
4,924
3,047
3,392

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
2,237
- -
Cash, Cash Equivalents & STI
- -
313
- -
Accounts Receivable, Net
- -
818
- -
Inventories
- -
701
- -
Total Current Liabilities
- -
879
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
416
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
37.54%
16.31%
29.33%
Free Cash Flow
-80.37%
84.09%
266.76%
Net Income, GAAP
108.65%
-0.65%
35.64%
Sales/Revenue/Turnover
12.4%
12.81%
21.67%
Total Cash Common Dividend
- -
- -
6.67%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
430
447
451
296
1,625
2026
430
472
469
606
1,978
2027
479
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
1.06
1.15
2.3
1.47
5.59
2026
1.59
1.56
1.21
3.28
7.11
2027
1.36
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
1
2026
- -
- -
- -
- -
1
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Rajesh Madan
Full Time Employees
405
Sector
Health technology
Industry
Pharmaceuticals: major
Address
1506, Chiranjiv Tower New Delhi DE India 110019
IPO Date
Jul 27, 1995
Website
medicamen.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Medicamen Biotech Limited manufactures and markets pharmaceutical formulations with a focus on oncology therapeutics and generics. The company offers a broad portfolio of products across therapeutic areas including cancer care, cardiology, central nervous system disorders, diabetology, anti-infectives, anti-malarials, vitamins, antibiotics, and pain management; its branded generics cover over 120 products, with specialized offerings in anti-hypertensives, antidiabetics, and sterile oncology injectables such as Bortezomib. Medicamen operates vertically integrated facilities for research and development, active pharmaceutical ingredients, and formulations, targeting regulated and emerging markets in the United States, Europe, Latin America, Asia-Pacific, Middle East, North Africa, and South Africa. Founded in December 1993 and headquartered in New Delhi, India, the company maintains manufacturing sites in Bhiwadi, Rajasthan, and Haridwar, Uttarakhand. Medicamen Lifesciences serves as a key subsidiary launched in 2022, concentrating on branded generics in cardiovascular, metabolic, and cardiac segments. Recent developments include USFDA approval for its sterile oncology facility in Haridwar and Bhiwadi plant, EU GMP certification for the Bhiwadi facility from Greece's National Organisation for Medicines, a 10-year manufacturing and supply agreement with a leading US and European pharma distributor utilizing its USFDA-approved oncology unit, a CDMO contract with European firm XGX Pharma to develop and manufacture six products, and a strategic partnership with a South African conglomerate for product registration and marketing in that $4 billion regulated market.